We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease (MMACKD)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2015 by Grigorios G. DIMAS, Aristotle University Of Thessaloniki.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01458158
First Posted: October 24, 2011
Last Update Posted: February 23, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
AHEPA University Hospital
Information provided by (Responsible Party):
Grigorios G. DIMAS, Aristotle University Of Thessaloniki
  Purpose
The purpose of this study is to determine whether matrix metalloproteinases are associated with atherosclerosis in the different stages of chronic kidney disease.

Condition
Diabetic Nephropathy

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: The Role of Matrix Metalloproteinases -2 and -9 in Atherosclerosis of Patients With Chronic Kidney Disease

Resource links provided by NLM:


Further study details as provided by Grigorios G. DIMAS, Aristotle University Of Thessaloniki:

Primary Outcome Measures:
  • Association of matrix metalloproteinases with atherosclerosis in patients with chronic kidney disease [ Time Frame: two years ]
    Matrix metalloproteinases associated with atherosclerosis in chronic kidney disease;patients with diabetes mellitus type 2 and others with chronic glomerulonephritis.Serum levels of MMPs-2 and -9 are measured by an ELISA system.Intima Media Thickness(IMT) of carotid and femoral arteries is measured with a high resolution ultrasonography.


Secondary Outcome Measures:
  • Matrix metalloproteinases and atherosclerosis associated with pro-inflammatory and oxidative stress markers in chronic kidney disease [ Time Frame: two years ]
    Matrix metalloproteinases associated with atherosclerosis markers,pro-inflammatory markers and markers of oxidative stress in chronic kidney disease


Biospecimen Retention:   Samples Without DNA
serum and vessels

Estimated Enrollment: 300
Study Start Date: October 2011
Estimated Study Completion Date: May 2016
Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts
Diabetic nephropathy
Diabetic nephropathy in patients with type 2 diabetes
chronic glomerulonephritis
chronic glomerulonephritis in patients without diabetes mellitus
controls
participants without diabetic nephropathy and chronic glomerulonephritis

Detailed Description:
The purpose of this study is to determine the correlation of matrix metalloproteinases and atherosclerosis of chronic kidney disease. Patients with diabetes mellitus type 2,as a non-inflammatory leading cause of end stage renal failure and patients with chronic glomerulonephritis and similar course of proteinuria,as an inflammatory leading cause of end stage renal failure are enrolled.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients from University Hospital AHEPA
Criteria

Inclusion Criteria:

  • Chronic kidney disease
  • Diabetes mellitus type 2

Exclusion Criteria:

  • Malignancy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01458158


Contacts
Contact: Grigorios G. Dimas +0030 6972321534 gregorydimas@yahoo.gr

Locations
Greece
AHEPA University Hospital, Medical School of Aristotle University of Thessaloniki Recruiting
Thessaloniki, Greece
Principal Investigator: Grigorios G. Dimas, MD         
Sponsors and Collaborators
Aristotle University Of Thessaloniki
AHEPA University Hospital
Investigators
Principal Investigator: Grigorios G. Dimas, MD AHEPA University Hospital,Medical School of Aristotle University of Thessaloniki
  More Information

Responsible Party: Grigorios G. DIMAS, Doctor/PhD Candidate, Aristotle University Of Thessaloniki
ClinicalTrials.gov Identifier: NCT01458158     History of Changes
Other Study ID Numbers: A13749
31-8-2010 ( Other Identifier: AristotleU )
First Submitted: September 30, 2011
First Posted: October 24, 2011
Last Update Posted: February 23, 2015
Last Verified: February 2015

Keywords provided by Grigorios G. DIMAS, Aristotle University Of Thessaloniki:
Gelatinases
kidney disease
diabetes mellitus type 2

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Atherosclerosis
Diabetic Nephropathies
Urologic Diseases
Renal Insufficiency
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases